Posts With Tag Gilead Sciences

Gilead Sciences, Inc. (GILD) files an 8-K report detailing significant events on October 6, 2025. Essential for investors and analysts tracking NASDAQ updates.

Discover Gilead Sciences' significant 8-K filing dated August 10, 2025. Stay informed on crucial developments impacting stock GILD and shareholder interests.

Explore Gilead Sciences' Q2 2025 financial report showcasing revenue growth in HIV therapy. Key insights on profitability, expenses, and market outlook for informed investment decisions.

Explore Gilead Sciences, Inc.'s 8-K report detailing significant corporate changes and events affecting investors as of August 7, 2025. Stay informed on GILD's latest developments.

Discover Gilead Sciences, Inc.'s latest 8-K filing revealing significant shareholder updates as of July 30, 2025. Stay informed on GILD stock and financial transparency.

Explore Gilead Sciences' 8-K filing detailing significant events on May 7, 2025. Stay informed on market implications for GILD shareholders.

Explore Gilead Sciences' Q1 2025 financial report, highlighting $6.647B revenue, $1.315B net income, and a positive outlook for investors. Key insights on profitability and R&D investments.

Explore Gilead Sciences, Inc.'s latest 8-K filing, revealing crucial updates on their common stock and corporate events as of April 24, 2025. Stay informed!

Explore the current challenges in the biotech sector and discover resilient companies like Amgen, Gilead, Moderna, Illumina, and Vertex that present promising investment opportunities.

Explore Gilead Sciences' financial performance, highlighting revenues, legal challenges, and future outlook. Key insights for investors considering a hold strategy.

Explore Gilead Sciences' 8-K report detailing key financial metrics and company updates as of March 9, 2025. Essential insights for investors and stakeholders.

Explore Galapagos NV's Form 6-K for February 2025, detailing the Separation Agreement with Gilead and implications for shareholders. Key risks and forward-looking statements included.